uniQure 
uniQure is a world-leading gene therapy company. Our lead product, Glybera, received a positive opinion from CHMP in July 2012 and is poised to become the first gene therapy approved in the Western World, capping more than 30 years research in this area.
This positive outcome validates uniQure's AAV platform and, most importantly, the only commercially scalable manufacturing system currently available anywhere.
uniQure's plug-and-play platform offers the opportunity to develop many additional therapies on a platform that is now validated and accepted as safe by regulatory authorities.
uniQure's second programme, for Hemophilia B ($1.5bn market) is in a Phase I/II clinical study and has shown up to 30 months stable, therapeutic expression from a single treatment (NEJM Dec 2011).
Over the coming 6 months further programmes for Porphyria, Parkinson's Disease and Sanfilippo B are expected to enter Phase I/II clinical trials.
uniQure is based in Amsterdam, and backed by Forbion, Gilde, Advent, CAPE and other investors. We would be interested in meeting to discuss potential collaborations and also potential investment opportunities.
